🔗 Share this article

Given that the US continues making historic revisions to its vaccine guidelines, an unexpected name appears in a surprising turn: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning Covid vaccinations during the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Program

Public health authorities had intended to reveal radical revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US at odds with many the world with insufficient data for benefit. The announcement has been pushed back until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

A New Direction at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing certain childhood shot schedules in the US so as to align more like Denmark, a society with comprehensive healthcare and a population about the population of Wisconsin’s.

To date comments, she has continued to focus on immunizations – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Expertise

The appointee has no apparent background in drug development, oversight or management, which has been standard for former directors of the biologics center. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Previous commissioners of the center would “understand legal statutes and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that previous people who headed the center have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“The public just focuses on the innovative therapies, but the generic drug division clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, non-prescription drug unit and so forth, and each of these need to be managed,” she explained. “The thing you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a significant leadership aspect to the role, which manages over 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” the former official added.

Agency Reaction and Controversial Policies

Regarding inquiries about Dr. Høeg's qualifications and whether this appointment indicates more teamwork among agency officials on immunizations, a representative responded that the “questions stem from flawed assumptions”.

“Her resume is consistent with the responsibilities of her role,” the spokesperson explained, noting the period Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's recently launched priority voucher program, a contentious rapid therapy clearance system that reportedly concerned her former heads. “How are these medications being selected for this voucher program? Who takes the choices?” Howard asked. “There is a lot of secrecy going on at the agency right now.”

Overall, he stated, “the agency appears to be shifting towards laxer regulations of most medications, except for immunizations.”

Documented Track Record on Immunizations

Concerning vaccines, Høeg has a clearer, if problematic, track record, some experts observe. She authored a research paper using unverified volunteer-provided data to determine the rate of myocarditis after COVID-19 immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the new federal leadership encompassed changing rules for recently developed shots and ending “optional” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of barring teenage boys from getting COVID-19 vaccinations.

“She’s an complete dogmatist who commences with her preconceived notions and reverse-engineers to fit the data in a extremely deceptive, untruthful fashion,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other dissenters, {like|